Outpatient treatment of children and adolescents with antipsychotic drugs in Croatia

Nordic Journal of Psychiatry

Volumn 66, Issue 1, 2012, Pages 2-7

  Maranić, Vlatka Boričević ^a   Dodig Ćurković, Katarina ^b   Juretić, Zoran ^a  

^a Psychiatric Hospitalfor children and adolescents   (Croatia)

^b University Health Center Osijek   (Croatia)

Author keywords

Adolescents; Antipsychotics; Atypical antipsychotics; Children; Outpatient treatment

Indexed keywords

HALOPERIDOL; LEVOMEPROMAZINE; NEUROLEPTIC AGENT; OLANZAPINE; PROMAZINE; QUETIAPINE; RISPERIDONE;

ADOLESCENT; ADOLESCENT HEALTH; ADULT; ARTICLE; AUTISM; BEHAVIOR DISORDER; CHILD; CHILD PSYCHIATRY; CROATIA; DEVELOPMENTAL DISORDER; FEMALE; GROUPS BY AGE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DEFICIENCY; MONOTHERAPY; MOOD DISORDER; OUTPATIENT; PRESCRIPTION; PSYCHOSIS; SCHOOL CHILD; SEX DIFFERENCE; TIC DIORDER; TIC DISORDER;

ADOLESCENT; AMBULATORY CARE; ANTIPSYCHOTIC AGENTS; CHILD; CROATIA; FEMALE; HUMANS; MALE; MENTAL DISORDERS; OFF-LABEL USE; PSYCHOTIC DISORDERS; RETROSPECTIVE STUDIES;

EID: 84855645508     PISSN: 08039488     EISSN: 15024725     Source Type: Journal    
DOI: 10.3109/08039488.2011.556198     Document Type: Article

References (23)

1. Olfson M, Blanco C, Liu L, Moreno C, Gonzalo Laje G. National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry 2006;63:679-85. (Pubitemid 43848299)
2. Rani F, Murray ML, Byrne PJ, Wong IC. Epidemiological features of antipsychotic prescribing to children and adolescents in primary care in the United Kingdom. Pediatrics 2008;121:1002-9.
3. Kalverdijk LJ, Tobi H, van den Berg PB, Buiskool J, Wagenaar L, de Jong-van den Berg LTW. Use of antipsychotic drugs among Dutch youths between 1997 and 2005. Psychiatr Serv 2008;59:554-60.
4. Schubert I, Lehmkuhl G. Increased antipsychotic prescribing to youths in Germany. Psychiatr Serv 2009;60:269.
5. Deurell M, Weischer M, Pagsberg AK, Labianca J. The use of antipsychotic medication in child and adolescent psychiatric treatment in Denmark. A cross-sectional survey. Nord J Psychiatry 2008;62:472-80.
6. Hugtenburg JG, Heerding ER, Tso YH. Psychoacitve drug prescribing in Dutch child and adolescent psychiatrists. Acta Paediatr 2005; 94:1484-87. (Pubitemid 41510662)
7. Correll CU. Antipsychotic use in children and adolescents: Minimizing adverse effects to maximize outcomes. J Am Acad of Child and Adolesc Psychiatry 2008;47:9-20.
8. Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK. Cardiometabolic risk of second-generation antipsychotic medications during fi rst-time use in children and adolescents . JAMA 2009;302:1765-73.
9. Fedorowicz VJ, Fombonne E. Metabolic side effects of atypical antipsychotics in children: A literature review. J Psychopharmacol 2005;19:533-50. (Pubitemid 41392308)
10. Rosenbloom AL. Hyperprolactinemia with antipsychotic drugs in children and adolescents. Int J Pediatr Endocrinol 2010;2010. pii: 159402. Epub 2010 Aug 24.
11. Panagiotopoulos C, Ronsley R, Elbe D, Davidson J, Smith DH. First do no harm: Promoting an evidence-based approach to atypical antipsychotic use in children and adolescents. J Can Acad Child Adolesc Psychiatry 2010 May;19:124-37.
12. A deponle AB, Obembe AO, Nnaji F, Adeyemi SO, Suleiman GT. Psychotropic drugs prescription at two regional psychiatric hospitals in northern Nigeria. West Afr J Med 2008;27:106-10.
13. Staller JA, Wade MJ, Baker M. Current prescribing patterns in outpatient child and adolescent psychiatric practice in central New York. J Child Adolesc Psychopharmacol 2005;15:57-61. (Pubitemid 40365914)
14. Pappadopulos E, Jensen PS, Schur SB, Maclntyre II JC, Ketner S, Van Orden K, et al. "Real world "atypical antipsychotic prescribing practices in public child and adolescent inpatient settings. Schizophr Bull 2002;28:111-21. (Pubitemid 34534755)
15. Arcelus J, Vostanis P. Child psychiatric disorders among primary mental health service attenders. Br J Gen Pract 2003;53:214-16. (Pubitemid 36300905)
16. Wong ICK, Murray ML, Camilleri-Novak D, Stephens P. Increased prescribing trends of paediatric psychotropic medications. Arch Dis Child 2004;89:1131-2.
17. Aman MG, Hollway JA, Leone S, Masty J, Lindsay R, Nash P, Arnold LE. Effects of risperidone on cognitive-motor performance and motor movements in chronically medicated children. Res Dev Disabil 2009;30:386-96.
18. Armenteros JL, Lewis JE, Davalos M. Risperidone augmentation for treatment-resistant aggression in attention-defi cit/hyperactivity disorder: A placebo-controlled pilot study. J Am Acad Child Adolesc Psychiatry 2007;46:558-65. (Pubitemid 46642572)
19. Reyes M, Buitelaar J, Toren P, Augustyns I, Eerdekens M. A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders. Am J Psychiatry 2006;163:402-10. (Pubitemid 44469381)
20. LeBlanc JC, Binder CE, Armenteros JL, Aman MG, Wang JS, Hew H, Kusumakar V. Risperidone reduces aggression in boys with a disruptive behaviour disorder and below average intelligence quotient: Analysis of two placebo-controlled randomized trials. Int Clin Psychopharmacol 2005;20:275-83. (Pubitemid 41192148)
21. Aman MG, Binder C, Turgay A. Risperidone effects in the presence/absence of psychostimulant medicine in children with ADHD, other disruptive behavior disorders, and subaverage IQ. J Child Adolesc Psychopharmacol 2004;14:243-54. (Pubitemid 38988790)
22. Findling RL. Atypical antipsychotic treatment of disruptive behavior disorders in children and adolescents. J Clin Psychiatry 2008;69:9-14.
23. Dean AJ, McDermott BM, Marshall RT. Psychotropic medication utilization in a child and adolescent mental health service. J Child Adolesc Psychopharmacol 2006;16:273-85. (Pubitemid 43902424)